Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Orkin Canada, a wholly owned subsidiary of Rollins, Inc., alerts Canadian homeowners to increased carpenter ant activity during spring and provides tips to prevent infestations that can cause structural wood damage. The company highlights the importance of moisture control, sealing entry points, clearing wood debris, and vegetation management to mi…
Enphase Energy, Inc. has opened U.S. pre-orders for its new IQ9S-3P Commercial Microinverter, the company's most powerful microinverter yet. Utilizing advanced gallium nitride (GaN) technology, the device supports high-wattage panels up to 770 W and is designed for three-phase 480V grid configurations. The product aims to optimize energy production…
Gildan Activewear Inc. released its 22nd Sustainability Report showcasing continued achievements under its Next Generation Sustainability strategy. In 2025, the company met its sustainable cotton sourcing goals, reduced water intensity by approximately 25%, increased recycled fiber usage, and enhanced health and safety standards with ISO certificat…
Axon Enterprise shares edged lower after investor Rahul Kishore presented the company at the Sohn investment conference at Lincoln Center. Kishore, founder of Epicenter Capital and former Coatue executive, framed Axon's growth prospects around artificial intelligence. The presentation included an AI-generated introduction from an assistant named Ev…
Swarmer, Inc., a U.S.-based drone autonomy software company, announced a $2.86 million contract awarded by Meta Bureau LLC to outfit over 16,000 SkyKnight quadcopter UAVs with its swarming software platform. The deal includes options to upgrade licenses potentially worth an additional $10.4 million. Swarmer's battle-tested AI-based software has sup…
UBS has reiterated a bullish stance on select large European energy companies following a solid first-quarter earnings period. The broker points to robust oil trading, resilient refining margins and enhanced shareholder returns as drivers behind a sector-wide 6% earnings beat, and names TotalEnergies and Eni as its preferred picks while upgrading B…
On May 13 a German court determined that Mondelez misled consumers by reducing the net weight of some Milka chocolate bars from 100 grams to 90 grams while leaving the packaging largely unchanged. The ruling, brought forward by a consumer protection agency, requires a clear notice on packaging for at least four months after the change to prevent co…
Heightened attention on Greenland following former U.S. President Donald Trump’s declaration about the island has triggered renewed business interest, with Danish export credit agency EIFO arguing that expanding tourism infrastructure could produce local economic benefits more quickly than mining. Officials in Greenland stress environmental protect…
Wolfspeed shares soared in pre-market trading after an influential research note singled out the silicon carbide specialist as a top pick tied to AI infrastructure growth. The move followed a sequence of corporate developments - including sequential AI data center revenue gains, a substantial debt refinance and redemption, and a technical wafer mil…
Carrefour shares climbed about 1% after the Paris Court of Appeal found that the Rennes Commercial Court does not have jurisdiction over claims lodged by the Carrefour Franchisees Association (AFC). The judgment overturns the earlier decision, affirms the validity of arbitration clauses in Carrefour's franchise contracts, and requires any future cl…
HSBC chief multi-asset strategist Max Kettner retains the bank’s most bullish allocation to global equities, arguing that positioning is not signalling a sell and that systematic investors have capacity to add. The bank stays overweight equities, emerging market local debt and high-yield credit, while remaining most underweight U.S. Treasuries vers…
Barclays launched coverage of Belimo Holding AG with an overweight rating and a CHF 1,000 price target, highlighting the company’s exposure to liquid cooling for data centers as a significant and underappreciated growth driver. The broker projects strong top-line growth and margin expansion through 2028, driven by accelerating deployment of power-d…
Sempra's exposure to Oncor and a reported 127 GW pipeline in Texas creates a levered growth story that the market is under-pricing. With market cap near $61B and EV around $96B, the stock at ~$93 offers upside if Oncor-related projects begin to monetize. We'll lay out an actionable long trade with an entry, stop and target, and the key catalysts an…
RBC Capital Markets upgraded Swatch Group to Sector Perform from Underperform and raised its price target to 220 Swiss francs after the company announced a collaboration with Audemars Piguet. RBC models material revenue and EBIT contributions from the 'Royal Pop' pocket watch collection, but the stock tumbled more than 6% amid investor disappointme…
Rocket Lab (RKLB) is trading at premium multiples after a record Q1 print and a string of contracts. The shares look overbought technically, but a $2.2B backlog, rising revenue and a clear product roadmap (including the Neutron test in Q4 2026) give me enough conviction to upgrade to Buy with a disciplined entry, stop and target.
Dyne Therapeutics, a clinical-stage biopharmaceutical company focused on genetically driven neuromuscular diseases, announced its management team's participation in three major 2026 investor healthcare conferences with live fireside chats and meetings. The company is advancing clinical and preclinical programs for diseases including Duchenne muscul…
Arbutus Biopharma reported robust financial results for Q1 2026 driven by a $179 million estimated license revenue from a patent litigation settlement with Moderna. The company ended the quarter with $95.2 million in cash and equivalents. Additionally, FDA granted Fast Track designation to Arbutus's hepatitis B drug candidate imdusiran, potentially…
Pyxis Oncology, a clinical-stage biotech company focusing on difficult-to-treat cancers, announced its management team's participation in three upcoming investor conferences where they will present updates. The company is advancing its lead candidate, micvotabart pelidotin (MICVO), an antibody drug conjugate targeting tumor-specific fibronectin, cu…
Dragonfly Energy Holdings Corp. has unveiled a redesigned e-commerce website for its Battle Born Batteries brand, aiming to improve customer navigation, education, and support for both retail and commercial clients. The new platform features improved accessibility, a faster interface, expanded educational resources, and better support tools for pro…
Abeona Therapeutics reported Q1 2026 financial results with increasing commercial adoption of its gene therapy ZEVASKYN, treating three patients and expanding qualified treatment centers to six. The company licensed novel engineered T-cell technology ABO-701 targeting advanced prostate cancer, aiming to file an IND in H2 2027 while deprioritizing o…
BrainsWay Ltd., a leader in noninvasive neurostimulation treatments, announced robust Q1 2026 financial results with revenue growing 35% to $15.5 million and net income more than doubling to $2.3 million year-over-year. The company shipped a record 117 Deep TMS systems in the quarter, expanded insurer coverage including for a new accelerated protoc…
Palvella Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for serious, rare skin diseases and vascular malformations, has successfully uplisted its common stock from the Nasdaq Capital Market to the Nasdaq Global Market. This uplisting reflects the company's fulfillment of higher listing standards and aims to boos…
BriaCell Therapeutics announced the inclusion of Penn Medicine’s Abramson Cancer Center as a clinical trial location for its ongoing pivotal Phase 3 study evaluating Bria-IMT, an immunotherapy regimen for advanced breast cancer. This expansion reflects increased interest from leading cancer centers and sustained enrollment momentum, with the trial …
Hengrui Pharma and Kailera Therapeutics announced they will present clinical trial data on ribupatide, a GLP-1/GIP receptor dual agonist for obesity treatment, at the American Diabetes Association 86th Scientific Sessions in June 2026. Hengrui will share Phase 2 oral ribupatide results, while Kailera presents data from its Phase 1 bridging study su…
Altimmune, Inc. disclosed its Q1 2026 financial results highlighting robust cash reserves of approximately $535 million as of April 30, 2026. The company plans to initiate the global PERFORMA Phase 3 trial for pemvidutide targeting metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2026, with important data readouts from …
